Use of ursodeoxycholic acid in patients with hypertransaminasemia

Ursodeoxycholic acid (UDCA) is a hydrophilic bile acid deriving from 7β epimerization of primary bile compound chenodeoxycholic acid. It may have antioxidant, immunomodulatory, antifibrotic and cytoprotective effects, therefore it has been extensively used in the treatment of cholestatic chronic liver diseases (primary biliary cirrhosis, primary sclerosing cholangitis, cholestasis of pregnancy, etc.). Due to the effectiveness of UDCA in decreasing serum liver enzyme levels also in non-cholestatic patients with chronic liver damage of various etiologies, this bile acid is now extensively used in clinical practice in combination with standard therapies, or as alternative treatment. In this paper, after a review of the biochemistry and physiology of UDCA, we have analyzed available data from the international literature on the efficacy and safety of UDCA in patients with hypertransaminasemia due to non-cholestatic chronic liver diseases, such as chronic viral hepatitis B and C and liver steatosis, the three main causes of aminotransferase elevation in western countries

Consequences of the COVID-19 pandemic on admissions to general hospital psychiatric wards in Italy: Reduced psychiatric hospitalizations and increased suicidality

Aims: The present investigation aimed at evaluating differences in psychiatric hospitalizations in Italy during and after the lockdown due to the novel coronavirus disease 2019 (COVID-19), compared to the same periods in 2018 and 2019. Methods: We obtained and analyzed anonymized data on psychiatric admissions (n = 4550) from 12 general hospital psychiatric wards (GHPWs) in different Italian regions (catchment area = 3.71 millions of inhabitants). Using a mixed-effects Poisson regression model, we compared admission characteristics across three periods: (a) March 1-June 30, 2018 and 2019; (b) March 1-April 30, 2020 (i.e., lockdown); and (c) May 1-June 30, 2020 (i.e., post-lockdown). Results: During the COVID-19 lockdown, there was a 41% reduction (IRR = 0.59; p 65 years) was observed in the lockdown (40%; IRR = 0.60; 95% CI: 0.44-0.82) and post-lockdown (28%; IRR = 0.72; 95% CI: 0.54-0.96) periods. Long-stay admissions (>14 days) increased (63%; IRR = 1.63; 95% CI: 1.32-2.02) during the lockdown and decreased by 39% thereafter (IRR = 0.61; 95% CI: 0.49-0.75). A significant 35% increase in patients reporting suicidal ideation was observed in the post-lockdown period, compared to the rate observed in the 2018 and 2019 control period (IRR = 1.35; 95% CI: 1.01-1.79). Conclusion: The COVID-19 lockdown was associated with changes in the number of psychiatric admissions, particularly for older patients and long-stay hospitalizations. Increased admission of patients reporting suicidal ideation in the post-lockdown period merits special attention. Further studies are required to gain insight into the observed phenomena